Загрузка...
Comparison of efficacy and safety of oral agents for the treatment of relapsing–remitting multiple sclerosis
In the therapeutic scenario of disease-modifying therapies for relapsing–remitting multiple sclerosis, the introduction of oral agents, starting in 2010 with fingolimod, has been a huge step forward in therapeutic options due to the easier administration route. Three oral drugs fingolimod, terifluno...
Сохранить в:
| Опубликовано в: : | Drug Des Devel Ther |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5546180/ https://ncbi.nlm.nih.gov/pubmed/28814828 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S137572 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|